Acer Therapeutics Management

Chris Schelling

CEO & Founder
Chris Schelling has 18 years of biotech and pharma strategic and orphan drug expertise. Prior to founding Acer, he was Executive Director of Strategic Marketing at BioMarin Pharmaceutical (BMRN), where he was instrumental in the development and commercialization of the company’s phenylketonuria (PKU) franchise. Previously, he held roles at Abgenix, Cell Therapeutics, Stanford Research Institute Consulting, and Organon.

William T. Andrews, M.D., FACP

Chief Medical Officer
Dr. Will Andrews joined Acer Therapeutics as Chief Medical Officer in October of 2017. He has worked in the biotech/pharmaceutical industry for 17 years in both Clinical Development and Medical Affairs, and has worked in multiple therapeutic areas, with a focus and extensive experience in rare diseases. Dr. Andrews has significant medical marketplace and product launch experience, having served as the medical lead for six product launches, including Xopenex HFA®, Brovana®, Alvesco®, Omnaris®, Catena®, and Juxtapid®. Most recently, he provided strategic consulting services to rare disease companies in Clinical Development, Medical Affairs, Go-To-Market/Launch planning, and Business Development/Corporate Strategy. Previously, Dr. Andrews held senior leadership positions and positions of increasing responsibility at Aegerion Pharmaceuticals, Santhera Pharmaceuticals, Sepracor, and ClinQuest. He received his undergraduate degree in Biology from Harvard University and his MD degree from Yale University School of Medicine. Dr. Andrews practiced medicine for 7 years full-time and 11 years part-time in the Boston area as a Board Certified Internist and an Attending Physician at Brigham and Women’s Hospital, and was on the Clinical Faculty at Harvard Medical School.

Harry Palmin

Chief Financial Officer
Harry Palmin has more than 20 years of corporate experience. He spent 15 years at Novelos Therapeutics (NVLT), where he served as President and CEO and Board Director, and built the company from concept to a $500M peak market cap; raised $98 million in funding; and oversaw ten clinical studies in oncology (including pivotal Phase 3 studies) and infectious diseases. Previously, he held roles at Lehman Brothers and Morgan Stanley.

Pamela M. Williamson, RAC, FRAPS

Acting Vice President, Regulatory Affairs
Pamela Williamson, RAC, FRAPS, joins Acer with over 30 years of experience in regulatory affairs, quality assurance and compliance, pharmacovigilance, clinical and product development and manufacturing operations with the biopharmaceutical industry. Prior to joining Acer, Pam was senior vice president of global regulatory affairs and patient safety at Alexion Pharmaceuticals where she was responsible for supporting the development of late stage internal research and development and external business development efforts. During her tenure at Genzyme Corporation, Pam was senior vice president of regulatory affairs and corporate quality systems followed by senior vice president, global head, for regulatory affairs and compliance where she was responsible for optimizing approval timelines and maximizing the value of the international product portfolio and pipeline. Prior to that, she held several positions with Serono and Ares-Serono, where she directed numerous cross-functional, multilevel teams. She led strategic and operational aspects of regulatory affairs, directed finished drug product technology transfer, manufacturing, operations logistics, and materials management. Pam is a member of the board of trustees for the Albany College of Pharmacy and Health Sciences and a member of the Pharmaceutical Research and Manufacturers of America, Biotechnology Industry Organization, Massachusetts Biotechnology Council, Food and Drug Law Institute, Drug Information Association, and Regulatory Affairs Professionals Society (Fellow). She has an MBA from Northeastern University in Boston.

Jeff Davis

Acting Chief Business Officer
Jeff Davis has more than 25 years of business and corporate development expertise as well as orphan drug expertise; and has led or supported over thirty transactions with an aggregate value in excess of $1 billion across all major therapeutic platforms. He is a Partner at Extera Partners; and previously held roles at Genzyme, Archemix, ImmunoGen, GenVec and Eli Lilly.